This page contains a Flash digital edition of a book.
Platelets – From Function to Dysfunction in Essential Thrombocythaemia


thrombocythemia (ET): clinical facts and biochemical riddles, Blood Cells Mol Dis, 2006;36:379–84.


50. Avram S, Lupu A, Angelescu S, et al., Abnormalities of platelet aggregation in chronic myeloproliferative disorders, J Cell Mol Med, 2001;5:79–87.


51. Mitus AJ, Schafer AI, Thrombocytosis and thrombocythemia, Hematol Oncol Clin North Am, 1990;4:157–78.


52. Mayordomo O, Carcamo C, Vecino AM, et al., Arachidonic acid metabolism in platelets of patients with essential thrombocythaemia, Thromb Res, 1995;78:315–21.


53. Holme S, Murphy S, Platelet abnormalities in myeloproliferative disorders, Clin Lab Med, 1990;10:873–88.


54. van Genderen PJ, Lucas IS, van SR, et al., Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation, Thromb Haemost, 1996;76:333–8.


55. Harrison CN, Campbell PJ, Buck G, et al., Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia, N Engl J Med, 2005;353:33–45.


56. Marchioli R, Finazzi G, Landolfi R, et al., Vascular and neoplastic risk in a large cohort of patients with polycythemia vera, J Clin Oncol, 2005;23:2224–32.


57. Arampatzis S, Stefanidis I, Lakiopoulos V, et al., Postpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature, Thromb J, 2010;8:12.


58. Harrison C, Pregnancy and its management in the Philadelphia negative myeloproliferative diseases,


Br J Haematol, 2005;129:293–306.


59. Passamonti F, Randi ML, Rumi E, et al., Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation, Blood, 2007;110:485–9.


60. Wright CA, Tefferi A, A single institutional experience with 43 pregnancies in essential thrombocythemia, Eur J Haematol, 2001;66:152–9.


61. Carobbio A, Antonioli E, Guglielmelli P, et al., Leukocytosis and risk stratification assessment in essential thrombocythemia, J Clin Oncol, 2008;26:2732–6.


62. Briere JB, Essential thrombocythemia, Orphanet J Rare Dis, 2007;2:3.


63. Falanga A, Marchetti M, Vignoli A, et al., V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules, Exp Hematol, 2007;35:702–11.


64. Furie B, Furie BC, Mechanisms of thrombus formation, N Engl J Med, 2008;359:938–49.


65. Marchetti M, Castoldi E, Spronk HM, et al., Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera, Blood, 2008;112:4061–8.


66. Lowe GD, Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture, Br J Haematol, 2006;133:232–50.


67. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al., Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential


thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden, Am J Hematol, 2009;84:102–8.


68. Negaard HF, Iversen PO, Ostenstad B, et al., Increased acquired activated protein C resistance in unselected patients with hematological malignancies, J Thromb Haemost, 2008;6:1482–7.


69. Villmow T, Kemkes-Matthes B, Matzdorff AC, Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes, Thromb Res, 2002;108:139–45.


70. Schafer AI, Turner NA, Handin RI, Platelet lipoxygenase- dependent oxygen burst. Evidence for differential activation of lipoxygenase in intact and disrupted human platelets, Biochim Biophys Acta, 1982;712:535–41.


71. Rodriguez-Linares B, Watson SP, Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation, Biochem J, 1996;316(1):93–8.


72. Royer Y, Staerk J, Costuleanu M, et al., Janus kinases affect thrombopoietin receptor cell surface localization and stability, J Biol Chem, 2005;280:27251–61.


73. Trappenburg MC, van Schilfgaarde M, Marchetti M, et al., Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia, Haematologica, 2009;94:911–8.


74. Sommeijer DW, Joop K, Leyte A, et al., Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes, J Thromb Haemost, 2005;3:1168–71.


EUROPEAN ONCOLOGY & HAEMATOLOGY


131


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68